A Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-On Therapy in Symptomatic Subjects With Pulmonary Arterial Hypertension (PAH)

Trial Profile

A Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-On Therapy in Symptomatic Subjects With Pulmonary Arterial Hypertension (PAH)

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Pharmacodynamics
  • Sponsors Bellerophon Therapeutics
  • Most Recent Events

    • 02 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 09 Feb 2016 Results from the final analysis of the long-term extension study published in a Bellerophon Therapeutics media release.
    • 24 Sep 2015 Results of interim analysis of data from part 2 of the trial published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top